Global Brain Tumor Drugs Market Size 2024, Forecast To 2033

The brain tumor drugs market has displayed strong growth, escalating from $3.55 billion in 2023 to $3.81 billion in 2024, with a compound annual growth rate (CAGR) of 7.3%. This growth in the historic period can be attributed to factors such as the increasing prevalence of neurological disorders, heightened healthcare expenditure, a surge in approvals for oncology drugs, augmented pharmaceutical R&D expenditure, and advancements in cancer drug discovery. Looking ahead to 2028, the market is poised for substantial growth, targeting $5.01 billion at a CAGR of 7.1%. The projected growth is influenced by factors including an increase in cancer incidence rates, a rise in healthcare expenditure, a growing geriatric population, a robust pipeline of drugs, and revised FDA regulations facilitating biologics drug development. Key trends in the forecast period encompass investments in combination drug therapies for brain tumor treatment, the adoption of phase zero clinical trials to enhance efficacy, the use of technology for drug delivery to improve efficacy, a focus on expanding cell and gene therapy, and strategic mergers and acquisitions.